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Abstract Rapid accurate detection is a prerequisite for the
successful control of meticillin-resistant Staphylococcus
aureus (MRSA). The IDI-MRSA real-time polymerase
chain reaction (PCR) assay was designed to provide rapid
results from nasal specimens collected in Stuart’s liquid
transport medium. This study has evaluated the IDI-MRSA
kit for use in a clinical laboratory by investigating the
following parameters: (1) limits of detection (LoD), (2)
performance with Amies’ gel-based transport medium, (3)
ability to detect strains of MRSA in a collection represen-
tative of MRSA in Ireland since 1974 (n=113) and (4)
performance in a clinical trial with swabs from nose,
throat and groin/perineum sites from 202 patients. LoDs
(colony-forming units per ml) of the IDI-MRSA kit, direct
culture on MRSA-Select chromogenic agar (CA) and salt-
enrichment culture (with subculture onto CA) were 103,
103 and 102, respectively. LoDs with Stuart’s and Amies’
transport media were comparable. All except one of the 113
MRSA isolates were detected by the kit but, when six
control strains carrying staphylococcal cassette chromo-
some mec (SCCmec) type IV element subtypes IVa–d and
SCCmec types V and VT were tested, the kit failed to detect
MRSA carrying SCCmec V. The sensitivity and specificity
for detection of MRSA from nose, throat and groin/
perineum specimens were comparable with slightly lower
sensitivities from throat and groin/perineum specimens
compared with nasal swabs (90%, 97%; 89%, 99%; 88%,
99%, respectively). Overall sensitivity, specificity and
positive and negative predictive values for specimens from
all sites were 88%, 99%, 94% and 97%, respectively.
Further developments to improve the sensitivity of this
highly worthwhile assay are required.
Introduction
Rapid detection of meticillin-resistant Staphylococcus au-
reus (MRSA) is important for the early implementation of
effective infection control [1]. Meticillin resistance is
encoded by mecA, which is carried on the staphylococcal
cassette chromosome mec (SCCmec). Previous molecular
methods for the rapid detection of MRSA have investigated
the presence of mecA and nuc or fem but have been unable
to distinguish between MRSA and mixtures of meticillin-
susceptible Staphylococcus aureus (MSSA) and meticillin-
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resistant coagulase-negative staphylococci (MR-CNS) [1].
The IDI-MRSA kit (GeneOhm Sciences Canada, Ste-Foy,
QC, Canada) overcomes this problem with a real-time
polymerase chain reaction (PCR) assay designed to detect
MRSA-specific DNA sequences within SCCmec, although
one study has shown that this method failed to detect 21
MRSA isolates and incorrectly identified 26 MSSA as
MRSA [2]. Newer versions of the kit (the most recent in
March 2006) incorporate modified primer and probe design
to improve efficacy but to date, there are no published
reports of the value of these modifications.
The IDI-MRSA kit is marketed as a screening method for
the detection of MRSA from nasal swabs from patients at risk
for colonisation with MRSA and has a quoted limit of
detection (LoD) of 325 colony-forming units (CFU) per swab
[3]. However, screening protocols relying on the culture of
nasal specimens alone may detect only 79% of MRSA
carriers, whereas culture of specimens from the nose, throat
and groin/perineum will detect up to 98% of carriers [4]. In
addition, the IDI-MRSA kit is validated for use with Stuart’s
liquid transport medium but many institutions use transport
swabs containing Amies’ gel-based transport medium. The
present study has been designed to evaluate the IDI-MRSA
kit for use in a clinical laboratory. The following parameters
have been investigated: (1) LoD, (2) performance with
Amies’ gel-based transport medium, (3) ability to detect
strains of MRSA in a collection representative of MRSA in
Ireland since 1974 and (4) performance in a clinical trial




LoD assays were performed on four MRSA isolates that
exhibited a range of oxacillin minimum inhibitory concen-
trations (MIC) and were representative of strains currently or
recently prevalent in Ireland [5, 6]. These isolates comprised:
(1) ST22-MRSA-IV, MIC >256 mg/l; (2) ST22-MRSA-IV,
MIC 32 mg/l; (3) ST8-MRSA-IID, MIC >256 mg/l; (4) an
isolate with an MIC of 4.0 mg/l that was mecA-positive by
PCR and expressed PBP2a but for which multilocus
sequence typing (MLST) data and SCCmec-typing results
were unavailable.
LoD assays were performed by preparing saline suspen-
sions of each isolate from overnight cultures grown on
Columbia agar (LabM Lab1; International Diagnostics
Group, Bury, UK) containing 7% (w/v) horse blood (blood
agar; BA) to a density equivalent to a 0.5 McFarland
turbidity standard. Following an initial 1/100 dilution,
suspensions were diluted in a series of 10-fold dilutions
(from 105 to 101). Colony counts (CFU/ml) for each
dilution were determined by spiral plating onto brain heart
infusion (BHI) agar (Oxoid CM375; Oxoid, Basingstoke,
UK) using a WASP spiral plater (Don Whitley Scientific,
Shipley, UK). Each dilution was adsorbed onto two Copan
Stuart’s liquid transport medium swabs (Copan 141C;
Copan Italia, Brescia, Italy) and used to determine the
LoD of each isolate in pure culture.
LoDs for all four MRSA isolates were also determined
in the presence of a “cocktail” of bacteria consisting of 10
MSSA isolates (which were mecA-negative by in-house
conventional PCR), five MR-CNS and single isolates of
Moraxella catarrhalis, Escherichia coli and Candida
species. All MSSA isolates were grown overnight on BA,
suspended in saline to a density equivalent to a 0.5
McFarland standard, pooled, diluted to approximately
106 CFU/ml, adsorbed onto a Copan transport swab and
tested with the IDI-MRSA kit (GeneOhm Sciences Canada).
The CNS and remaining bacterial species were prepared and
tested similarly. All isolates were combined to form a
“cocktail” to mimic normal flora and re-tested with the IDI-
MRSA kit to ensure that no false-positive results were
obtained. Ten-fold dilutions (from 105 to 101) of the four
test isolates were prepared by using the “cocktail” (at a set
concentration of 105 CFU/ml) as diluent and adsorbed onto
two Copan Stuart’s liquid transport medium swabs.
One Copan swab from each preparation of the four
MRSA isolates in pure culture and in the presence of mixed
flora was investigated for the presence of MRSA by using
the IDI-MRSA kit on a Smart Cycler II thermal cycler
(Cepheid, Sunnyvale, Calif., USA). The kit assay was
performed according to the manufacturer’s instructions with
two modifications. After the swabs were vortexed in sample
buffer, the tubes were centrifuged at 1,000 x g for 30 s to
minimize aerosol formation. To minimize the risk of
contaminating the negative control included in the kit,
aliquots sufficient for single use were dispensed into
individual microcentrifuge tubes. In all cases, real-time
PCR was performed immediately after DNA extraction.
Swabs tested with the IDI-MRSA kit were cultured by salt
enrichment by adding 1 ml tryptic soy broth (TSB; BD
211825; Becton Dickinson and Company, Sparks, Md, USA)
containing 6.5% NaCl (salt TSB) to the residual swabs in the
sample buffer tubes after the sample buffer had been removed.
After 18 h incubation at 35°C, enrichment broths (10-μl
volumes) were subcultured onto BA, MRSA-Select chromo-
genic agar (CA; Bio-Rad 63747; Bio-Rad Life Science Group,
Marnes La Coquette, France) and mannitol salt agar (BD
11407; Becton Dickinson) containing 5 mg/l meticillin
(Sigma M6535, Sigma-Aldrich, Poole, England) (MMSA).
The second swab of each of the MRSA preparations was
cultured onto BA, CA and MMSA. All isolates from
enriched and direct culture were identified as Staphyloco-
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ccus aureus by detecting staphylocoagulase production
(tube coagulase test) and, if necessary, clumping factor
(Pastorex Staph Plus; Bio-Rad). Meticillin resistance was
tested by disk diffusion at 30°C by using 10-μg meticillin
disks (Oxoid) on BA and with 30-μg cefoxitin disks on
Mueller-Hinton agar (BD 211438; Becton Dickinson)
according to Clinical and Laboratory Standards Institute
(CLSI) guidelines [7, 8]. LoDs for both culture methods
were calculated on the basis of growth of >1 colony on a
single subculture medium or ≥1 colony on more than one
subculture medium and were expressed as the average of
the counts obtained with the four isolates.
Evaluation of Transwabs with Amies’ clear transport
medium
Transwabs with Amies’ clear transport medium [MW170;
Medical Wire and Equipment (MWE), Corsham, England]
were evaluated by repeating the LoD determination of the
four test isolates in pure culture and in the presence of the
mixed flora “cocktail”. Test isolate suspensions were
adsorbed onto Transwabs, investigated by using the IDI-
MRSA kit and cultured as described above.
MRSA strains
In total, 119 isolates were investigated. These included 113
MRSA isolates representative of MRSA recovered in Ireland
and six control strains. The former comprised 89 isolates
representative of most epidemiological types recovered
between 1974 and 2003, six isolates that were not investigated
by MLST and SCCmec typing and 18 Panton-Valentine
leucocidin (PVL)-positive community-acquired MRSA [5,
6]. Details of these isolates are summarised in Table 1. The
six MRSA control strains represented isolates carrying
SCCmec IV subtypes IVa, IVb, IVc and IVd and SCCmec
V and VT because there were no data on MRSA carrying
these SCCmec elements in Ireland [9, 10].
Isolates were prepared at concentrations of ∼102 CFU/ml
above the LoD of the kit (as determined in the present
study) in saline suspensions containing ∼105 CFU/ml of the
mixed flora “cocktail” (described above), adsorbed onto
MWE Transwabs and tested by using the IDI-MRSA kit
according to the manufacturer’s instructions. After being
tested, all swabs were cultured by salt enrichment and
subcultured onto BA, CA and MMSA as described above.
Any isolate that was negative with the kit was re-tested
in pure culture and at one 10-fold higher concentration; if
still negative, the inoculum was further increased to
∼108 CFU/ml. The mecA status was confirmed by a
conventional in-house end-point PCR assay [11]. The
DNA extracted for conventional PCR was also tested by
using the IDI-MRSA kit. DNA extracted with the IDI-
MRSA kit from isolates still yielding negative results was
also tested by conventional PCR. DNA extracted with the
IDI-MRSA kit from Staphylococcus aureus ATCC 43300
was included as a positive control with this PCR assay.
Clinical trial
Clinical specimens were obtained from patients attending
St. James’s Hospital, a large 936-bed tertiary-referral adult
university teaching hospital. Specimens from nose, throat
and groin/perineum collected for routine MRSA screening
in the clinical microbiology laboratory were tested. Criteria
for routine screening were admission to a critical care area,
admission from another hospital or long-stay care institu-
tion, previous MRSA, recent hospitalisation in a foreign
hospital and pre- and post-operative cardiac surgery.
Specimens from 202 consecutive patients in whom all
three sites were sampled were included in the study.
Duplicate specimens from the same patient were excluded.
Specimens were tested with the IDI-MRSA kit after they
had been subjected to routine culture by direct inoculation
onto CA in the diagnostic laboratory. Specimens were
tested within 24 h of collection from the diagnostic
laboratory and stored at 4°C until investigations were
complete.
Table 1 Meticillin-resistant Staphylococcus aureus (MRSA) isolates
used to determine whether the IDI-MRSA kit could detect all strains
of MRSA prevalent in Ireland (n=113; ND not done, NT AR patterns
designated “no type” pending results of DNA macrorestriction
digestion analysis, PVL Panton-Valentine leucocidin, SCV small
colony variant, v previously reported variants of SCCmec [6, 20])
Multilocus
sequence type
SCCmec Antibiogram-resistogram (AR) type
ST5a (n=10) II 07.3a (n=3); 07.4 (n=5); 11 (n=2)
ST5 (n=1) IV Unfamiliarb (n=1)
ST8c (n=11) IV or
IVv
43 (n=8); unfamiliarb (n=3c)
ST8 (n=26) II or IIv 13 (n=8); 14 (n=15); New03 (n=3)
ST12 (n=1) IV NT (n=1)
ST22 (n=14) IV 06 (n=13); NT (n=1)
ST30 (n=2) IV NT (n=2)
ST36 (n=3) II 07.0 (n=2); 07.2 (n=1)
ST45 (n=1) IV NT (n=1)
ST239 (n=13) III or
IIIv
01 (n=4); 09 (n=3); 15 (n=2); 44
(n=3); 23 (n=1)
ST247 (n=3) IA 22 (n=2); New02 (n=1)
ST250 (n=4) I or Iv 02 (n=4)
ND (n=6) ND 07 (n=2); New02 (n=1); 06 (n=1);
SCV (n=2)
ND (n=18) ND PVL-positive community-acquired
MRSA (n=18)
a One isolate was a double locus variant of ST5
bUnfamiliar AR pattern
c Two isolates were single locus variants of ST8
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After being tested with the IDI-MRSA kit, all specimens
were cultured by salt enrichment as described above and
subcultured onto BA, CA and MMSA. Suspect colonies
were identified as MRSA as described above and the
presence of mecA was confirmed by a conventional in-
house end-point PCR assay [11]. MRSA isolates recovered
from specimens yielding kit-negative results were prepared
in suspensions at concentrations of 105 CFU/ml in the
presence of the mixed flora “cocktail”, adsorbed onto
Transwabs and re-tested by using the IDI-MRSA kit.
Bacterial growth from BA plates from specimens that
tested IDI-MRSA kit-positive but from which MRSA was
not recovered in culture was similarly tested to exclude the
possibility that such positive results occurred as a result of
MSSA or MR-CNS.
Control strains
Staphylococcus aureus ATCC 25923 and Staphylococcus
aureus ATCC 43300 were used as negative and positive
controls, respectively. Control isolates were prepared in saline
suspensions containing 105 CFU/ml, adsorbed onto appro-
priate swabs and processed with each batch of tests. Positive
and negative controls were included with each batch of tests
when determining LoDs. A negative control was included
with each batch of MRSA strains tested. A positive control
was included with every batch of specimens in the clinical
trial. Staphylococcus aureus ATCC 43300 was included with
each batch of CA and MMSA plates used.
Statistics
In the clinical trial, the sensitivity, specificity and positive and
negative predictive values (with 95% confidence intervals) of
the IDI MRSA kit were calculated for each specimen type
compared with direct culture, enrichment culture and the
combined results from both direct and enrichment culture
methods. The sensitivity, specificity and positive and negative
predictive values of the kit were also calculated from results
obtained from specimens from all sites.
Because the IDI-MRSA kit detects DNA that may come
from non-viable MRSA, whereas culture detects viable
organisms only, IDI-MRSA kit-positive specimens that
were culture-negative were considered as possible “true”-
positive results if the patient had been previously positive
for MRSA or if the patient was positive at another site.
Obversely, with salt enrichment culture, specimens from
patients with no record of being previously positive and
that yielded one or two colonies only on one of the two
selective media used were considered possible “false”-
positive results. Sensitivity, specificity and positive and
negative predictive values were also calculated by using
these “amended” results. Further calculations were made
when patients were grouped into those who were known to
have been previously positive for MRSA and those who
were not known to have been previously positive.
Results
LoD assays
LoDs of the IDI-MRSA kit, direct culture and salt
enrichment culture for the four test isolates prepared in
pure culture by using Stuart’s and Amies’ transport medium
swabs are shown in Table 2. The LoD of the IDI-MRSA kit
was 103 CFU/ml for both Stuart’s liquid transport medium
and Amies’ gel-based transport medium. This LoD was
comparable to the value obtained for direct culture but was
10-fold higher than the LoD of enrichment culture with
either transport medium. There was no appreciable differ-
ence in LoD values for isolates prepared in pure culture or
mixed flora, with both types of transport medium.
MRSA strains
Isolate suspensions were prepared in saline at a concentra-
tion of ∼105 CFU/ml (i.e. ∼102 CFU/ml above the LoD
determined in the present study). All isolates except two
yielded positive IDI-MRSA kit results. Both negative
isolates were mecA-positive by conventional PCR. One
isolate was a hetero-glycopeptide-intermediate Staphylo-
coccus aureus (hGISA) which was kit-positive when re-
tested in pure culture from a suspension at a concentration
of 105 CFU/ml. Five additional hGISA isolates (prepared
from suspensions at 105 CFU/ml) were tested with the kit
and all were positive. The second isolate that failed to yield
a positive IDI-MRSA kit result was a Staphylococcus
aureus control strain carrying the SCCmec V element. This
isolate remained negative with the IDI-MRSA kit when
tested in pure culture (at concentrations prepared from
Table 2 Limits of detection {LoD; average bacterial counts in
colony-forming units (CFU/ml)} for the IDI-MRSA kit, direct culture








Direct culture 1.3×103 0.8×103
Enrichment culture 1.4×102 2.4×102
a Bacterial counts (in CFU/ml) of saline suspensions adsorbed onto
relevant transport medium swabs prior to testing the swabs by each
method
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suspensions of 105, 106 and 108 CFU/ml) but DNA
extracted for conventional PCR yielded a positive result
when tested with the IDI-MRSA kit. Conversely, DNA
extracted with the IDI-MRSA kit was negative when tested
by conventional PCR but DNA extracted with the IDI-
MRSA kit from Staphylococcus aureus ATCC 43300 was
also negative by conventional methods. All isolates were
successfully recovered from suspensions containing mixed
flora when cultured by salt enrichment.
Clinical trial
A total of 606 specimens from 202 patients was investi-
gated. An overview of the numbers of positive specimens
by the IDI-MRSA kit, by direct and enrichment culture and
by “amended” results is shown in Table 3. MRSA was
detected in 120 specimens (20%, 120/606) from 63 patients
(31%, 63/202) by the IDI-MRSA kit, with 93 (15%) and
116 (19%) specimens being positive by direct and
enrichment culture, respectively. When the results of both
direct and enrichment culture methods were combined, 119
specimens from 61 patients were positive (20%, 119/606;
30%, 61/202). Of the 119 culture-positive specimens, 98
were positive by the IDI-MRSA kit. Twelve specimens
from 11 patients were unresolved on initial testing but, after
repeat testing following freezing at -20°C, only three
specimens remained unresolved.
Twenty-two culture-negative specimens were positive by
the IDI-MRSA kit but only 15 of these were deemed to be
true positives because the patients had a previous MRSA
isolate or were positive at another site. Twenty-six speci-
mens were positive by salt enrichment culture only but five
of these were deemed false-positive because only one or
two colonies grew from either CA or MMSA and the
patients had no previous MRSA and no other screening
sites that were positive. When calculations were performed
based on these “amended” results, 128 specimens (21%;
128/606) from 64 patients (32%; 64/202) were deemed
positive (Table 3).
When representative MRSA isolates recovered from six
of the 15 specimens that were IDI-MRSA kit-negative and
MRSA culture-positive were further investigated, all iso-
lates tested positive with the kit. Non-MRSA isolates
recovered from specimens that were kit-positive and MRSA
culture-negative were also tested by the kit but all isolates
yielded negative results with the IDI-MRSA kit.
Statistics
The sensitivity, specificity and positive and negative
predictive values (with 95% confidence intervals) of the
IDI-MRSA kit compared with direct culture, enrichment
culture and amended results are shown in Table 4. With
nasal swabs, the improved yield of MRSA following salt
enrichment resulted in a decrease in the comparative
sensitivity of the kit from 89% to 81% but when the
“amended” results were considered, the sensitivity of the kit
compared with culture (by both direct and enrichment
methods) was 90%. Amended results obtained from nose,
throat and groin/perineum specimens were comparable,
although sensitivity decreased slightly with throat and
groin/perineum specimens (from 90% to 89% and 88%).
When the IDI-MRSA kit results from specimens from all
sites were compared with “amended” culture results, the
overall sensitivity, specificity and positive and negative
predictive values were 88%, 99%, 94% and 97%, respec-
tively. When this analysis was restricted to specimens from
previously positive patients, the sensitivity was 92% but
dropped to 82% with specimens from patients with no
record of being previously positive. For the latter group, the
negative predictive value was 98% but these data should be
interpreted with caution because of the lower positivity rate
of 9% compared with the 39% positivity rate in specimens
from previously positive patients.
Discussion
The clinical need for the rapid detection of MRSA to
implement effective infection control measures requires that
the methods be both sensitive and specific. The inherent
sensitivity, specificity and speed of real-time PCR make
Table 3 Overview of results obtained with the IDI-MRSA kit and
culture from 606 specimens
Culture method IDI-MRSA kit
Positive Negative Total
Direct culture Positive 85 8 93
Negative 35 475 510
Enrichment culture Positive 97 19 116
Negative 23 464 487
Direct and enrichment Positive 98 21a 119
Negative 22 462 484
Direct and enrichment,
amended resultsb
Positive 113 15 128
Negative 7 468 475
Total 120 483 603c
a Of 26 specimens positive by salt enrichment only, five were deemed
false-positive because only one or two colonies grew from either CA
or MMSA and the patients had no previous MRSA and no other
screening sites that were positive
b Amended results included numbers of specimens that were culture-
positive and those that were positive by the IDI-MRSA kit but
culture-negative from previously positive patients or from patients
from whom a specimen from another site was positive
c Three isolates were unresolved by the IDI-MRSA kit
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this technique an ideal candidate for the swift identification
of MRSA [12]. The IDI-MRSA kit is the first commercial
molecular assay for the rapid detection of MRSA that can
distinguish specimens containing MRSA from those con-
taining mixtures of MSSA and MR-CNS [2].
The manufacturer’s instructions for the use of the IDI-
MRSA kit state that the kit has a LoD of 325 CFU per swab
[3], which is disappointingly high for a molecular detection
assay. However, the present study has found that the kit has
an even lower sensitivity, with the LoD being 10-fold
higher than the quoted value and no better than the LoD of
direct culture on CA. Although the CA used in the present
study (MRSA-Select) has recently been shown to recover
MRSAwith a sensitivity of 97%–99% compared with other
culture media [13, 14], a molecular assay would be
expected to have a lower LoD than culture [12]. However,
our study has shown that salt enrichment culture followed
by subculture onto CA and MMSA yields an improved
sensitivity and a 10-fold lower LoD compared with the kit.
The poor sensitivity demonstrated by the kit may occur
because of the small volume of template DNA (2.8 μl) used
in the kits, the complexity of the multiplex reactions, the
low assay volume utilised by the PCR and/or the relatively
crude DNA extraction protocol used.
In addition to assessing the sensitivity of the kit, the
present study aimed to evaluate whether Transwabs
containing Amies’ gel-based transport medium could be
used with the IDI-MRSA kit. Prior to testing, the possibility
that the gel consistency of Amies’ transport medium
compared with the liquid in Stuart’s transport medium
might adversely effect DNA extraction was considered but
the results obtained with the LoD assays showed that the
use of Amies’ transport medium did not result in any loss of
sensitivity.
Another question addressed was whether the kit could
detect all strains of MRSA prevalent in Ireland. With the
exception of one hGISA isolate, all isolates were detected.
The hGISA isolate was detected on repeat testing in pure
culture suggesting that the problem lay in the DNA
extraction protocol and not with detection of the SCCmec
element carried by the isolate. No difficulty was experi-
enced in obtaining positive results when an additional five
hGISA isolates were tested with the IDI-MRSA kit. The kit
also yielded a negative result with the control isolate
carrying SCCmec type V but a kit-positive result was
obtained from DNA extracted for conventional PCR. The
failure of the kit to detect these isolates suggests that the kit
may have difficulty extracting DNA from some isolates.
Addition of lysostaphin, prolonged or more vigorous
mixing or the use of another DNA extraction method are
aspects that remain to be investigated but it is worrying that
SCCmec V, which is one of the two SCCmec elements
associated with community-acquired MRSA, was not
detected.
Although the present study has shown that throat and
groin/perineum specimens are suitable for use with the IDI-
MRSA kit, the overall sensitivity of the kit in the clinical
trial was 88%, which is disappointingly low. Previous
evaluations of the IDI-MRSA kit quoted sensitivity values
of 92%–100% but comparisons were made against direct
culture on MSA and, when enrichment culture was used,
subcultures were made onto BA [15, 16]. More recently,
sensitivities of 89% with nasal specimens and 82% with
groin specimens were reported when comparison was made
a Direct and enrichment culture results
b Amended results: see footnote to Table 3
Table 4 Sensitivity, specificity and positive (PPV) and negative
(NPV) predictive values expressed as a percentage for the IDI-MRSA
kit compared with culture from nose, throat and groin/perineum
specimens (numbers in parentheses 95% confidence intervals, All,
PPP all sites from previously positive patients, All, NPP all sites from
patients with no record of being previously positive)
Culture mthod Site IDI-MRSA kit
Sensitivity Specificity PPV NPV
Direct Nose 89 (78–99) 89 (85–94) 63 (50–77) 97 (95–99.9)
Enrichment Nose 81 (70–93) 91 (87–96) 71 (59–84) 95 (91–98)
Both methodsa Nose 81 (70–93) 91 (87–96) 71 (59–84) 95 (91–98)
Amendeda,b Nose 90 (82–98) 97 (95–99.9) 92 (84–99.6) 97 (94–99.5)
Amendeda,b Throat 89 (82–99) 99 (98–100) 98 (93–100) 97 (94–99.5)
Amendeda,b Groin/perineum 88 (76–99) 99 (97–100) 93 (84–100) 98 (95–99.9)
Both methodsa All sites 82 (76–89) 96 (94–97) 82 (75–89) 96 (94–98)
Amendeda,b All sites 88 (83–94) 99 (97–99.6) 94 (90–98) 97 (95–98)
Both methodsa All, PPP 88 (80–94) 92 (87–96) 85 (77–91) 93 (89–97)
Amendeda,b All, PPP 92 (86–97) 99 (97–100) 98 (95–100) 95 (92–98)
Both methodsa All, NPP 68 (51–84) 98 (96–99) 72 (56–89) 97 (95–99)
Amendeda,b All, NPP 82 (68–96) 98 (97–99.6) 79 (65–94) 98 (97–99.8)
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against direct and enrichment culture on MSA containing
oxacillin (OMSA) [17]. Studies comparing culture media
selective for MRSA have shown that OMSA has sensitiv-
ities ranging from 60% to 84%, whereas the CA used in the
present study (MRSA-Select) has a sensitivity of 97%–99%
[1, 13, 14]. Another evaluation of the IDI-MRSA kit
reported a sensitivity of 100% for the kit compared with
culture on CHROMagar MRSA but, again, that medium
was found to have a sensitivity of only 83% [13, 18]. In the
present study, the inclusion of salt enrichment culture
increased the number of MRSA-positive specimens by
23% (21/93) and, as a result, the relative sensitivity of the
kit for nasal specimens decreased from 89% when
compared with direct culture, to 81% when compared with
salt enrichment culture. With a LoD of 103 CFU/ml and a
sensitivity of 82% for specimens from all sites among
patients who had no record of being previously positive for
MRSA, the IDI-MRSA kit is not a replacement for culture.
Whereas it was important to determine that both throat
and groin/perineum sites were suitable for use with the kit,
the cost of testing all three sites would be prohibitively
expensive (the kit price per test is approximately €25).
Although costs can be reduced by pooling specimens from
various sites in a selective broth and, following overnight
incubation, by using the kit to detect MRSA in the broth
culture, this method has been associated with a high rate of
false-positive results [19].
In the present study, when non-MRSA bacterial isolates
recovered on BA from MRSA-culture-negative kit-positive
specimens were investigated further, no isolates tested kit-
positive. It is unlikely that the kit-positive results occurred
because the kit was more sensitive than culture (because
salt enrichment culture was shown to be the more sensitive
detection method) but positive results may have occurred
because the kit detected DNA that may have derived from
non-viable organisms. Important questions in this regard
are how long does DNA remain detectable after successful
MRSA eradication and what should be the clinical
interpretation of such results. The possibility that a patient
from whom MRSA has been successfully eradicated might
subsequently re-acquire the organism is a further compli-
cation. Among MRSA isolates recovered from kit-negative
culture-positive specimens, all isolates yielded kit-positive
results when re-tested in saline suspensions at concentra-
tions of 105 CFU/ml. This finding suggests that the false-
negative results do not arise from an inability to detect a
particular SCCmec type but again may reflect the low
sensitivity of the kit or inadequate DNA extraction.
Although the kit produces rapid results relative to
enrichment culture, the overall assay time including sample
preparation takes approximately 2.5 h for batches of 12
specimens. It also has the disadvantage that results are
displayed only as positive, negative or unresolved and,
hence, information from amplification plots cannot be
accessed to aid in the interpretation of anomalous results.
Providing an overall evaluation of the kit is complicated
by the fact that the kit detects DNA, whereas culture detects
viable organisms. A major difficulty is defining “true”-
positive and -negative specimens. In the present study, data
were analysed by direct comparison with culture but, to
overcome the problem of considering all kit-positive
culture-negative specimens as false-positive results, kit
performance was also analysed by using “amended” results
where kit-positive culture-negative results from patients
who were previously positive for MRSA were regarded as
“true” positive results. Other studies have excluded speci-
mens from patients on anti-staphylococcal therapy and only
included patients fulfilling stringent criteria of high-risk for
MRSA acquisition [15, 16]. In the present study, no attempt
was made to pre-select patients on the basis of antibiotic
therapy or risk factors other than those considered for
routine MRSA screening in this institution. Although the
manufacturer specifies that the kit’s intended use is with
specimens from patients at high risk for MRSA, in clinical
practice, the need for rapid results may be equally pressing
in other groups of patients (for example, pre-operative
cardiac surgery patients). However, when data were
analysed from patients with no previous record of MRSA,
the sensitivity was 82%. The kit did, however, show the
highest negative predictive value with specimens from this
group of patients but the low prevalence of MRSA in this
group must be considered when interpreting results. In
conclusion, the kit can provide a rapid preliminary screen
for MRSA but the final result requires culture. Further
developments to improve the sensitivity of this highly
worthwhile assay are required.
Acknowledgements We thank Teruyo Ito (Juntendo University,
Tokyo, Japan) and Robert Daum (University of Chicago, Chicago,
Ill., USA) for the gift of SCCmec IV and SCCmec V control strains.
We are grateful to BioFact (Ireland) for providing the SmartCycler
platform and for supplying IDI-MRSA kits at an evaluation rate. The
experiments reported in this article comply with current laws in
Ireland.
References
1. Brown DF, Edwards DI, Hawkey PM, Morrison D, Ridgway GL,
Towner KJ, Wren MW (2005) Guidelines for the laboratory
diagnosis and susceptibility testing of methicillin-resistant Staph-
ylococcus aureus (MRSA). J Antimicrob Chemother 56:1000–
1018
2. Huletsky A, Giroux R, Rossbach V, Gagnon M, Vaillancourt M,
Bernier M, Gagnon F, Truchon K, Bastien M, Picard FJ, Belkum
A van, Ouellette M, Roy PH, Bergeron MG (2004) New real-time
PCR assay for rapid detection of methicillin-resistant Staphylo-
coccus aureus directly from specimens containing a mixture of
staphylococci. J Clin Microbiol 42:1875–1884
Eur J Clin Microbiol Infect Dis (2007) 26:459–466 465
3. Anon (2006) IDI-MRSA Assay Package Insert. http://www.
geneohm.com/english/idi_mrsa.htm. Cited 14 February 2007
4. Anon (1998) Revised guidelines for the control of methicillin-
resistant Staphylococcus aureus infection in hospitals. British
Society for Antimicrobial Chemotherapy, Hospital Infection
Society and the Infection Control Nurses’ Association. J Hospital
Infect 39:253–290
5. Rossney AS, Lawrence MJ, Morgan PM, Fitzgibbon MM, Shore
A, Coleman DC, Keane CT, O’Connell B (2006) Epidemiological
typing of MRSA isolates from blood cultures taken in Irish
hospitals participating in the European Antimicrobial Resistance
Surveillance System (1999–2003). Eur J Clin Microbiol Infect Dis
25:79–89
6. Shore A, Rossney AS, Keane CT, Enright MC, Coleman DC
(2005) Seven novel variants of the staphylococcal chromosomal
cassette mec in methicillin-resistant Staphylococcus aureus iso-
lates from Ireland. Antimicrob Agents Chemother 49:2070–2083
7. Hewitt JH, Coe AW, Parker MT (1969) The detection of
methicillin resistance in Staphylococcus aureus. J Med Microbiol
2:443–456
8. Clinical and Laboratory Standards Institute (2006) Performance
Standards for Antimicrobial Susceptibility Testing; Sixteenth
Informational Supplement. CLSI Document M100-S16. Clinical
and Laboratory Standards Institute, 940 West Valley Road, Suite
1400, Wayne, Pennsylvania 19087-1898, USA
9. Boyle-Vavra S, Ereshefsky B,Wang CC, DaumRS (2005) Successful
multiresistant community-associated methicillin-resistant Staphylo-
coccus aureus lineage from Taipei, Taiwan, that carries either the
novel staphylococcal chromosome cassette mec (SCCmec) type VT
or SCCmec type IV. J Clin Microbiol 43:4719–4730
10. Chongtrakool P, Ito T, Ma XX, Kondo Y, Trakulsomboon S,
Tiensasitorn C, Jamklang M, Chavalit T, Song JH, Hiramatsu K
(2006) Staphylococcal cassette chromosomemec (SCCmec) typing
of methicillin-resistant Staphylococcus aureus strains isolated in
11 Asian countries: a proposal for a new nomenclature for
SCCmec elements. Antimicrob Agents Chemother 50:1001–1012
11. Oliveira DC, Lencastre H de (2002)Multiplex PCR strategy for rapid
identification of structural types and variants of the mec element in
methicillin-resistant Staphylococcus aureus. Antimicrob Agents
Chemother 46:2155–2161
12. Cockerill FR 3rd, Smith TF (2004) Response of the clinical
microbiology laboratory to emerging (new) and reemerging
infectious diseases. J Clin Microbiol 42:2359–2365
13. Nsira SB, Dupuis M, Leclercq R (2006) Evaluation of MRSA
Select, a new chromogenic medium for the detection of nasal
carriage of methicillin-resistant Staphylococcus aureus. Int J
Antimicrob Agents 27:561–564
14. Stoakes L, Reyes R, Daniel J, Lennox G, John MA, Lannigan R,
Hussain Z (2006) Prospective comparison of a new chromogenic
medium, MRSASelect, to CHROMagar MRSA and mannitol-salt
medium supplemented with oxacillin or cefoxitin for detection of
methicillin-resistant Staphylococcus aureus. J Clin Microbiol
44:637–639
15. Warren DK, Liao RS, Merz LR, Eveland M, Dunne WM Jr (2004)
Detection of methicillin-resistant Staphylococcus aureus directly
from nasal swab specimens by a real-time PCR assay. J Clin
Microbiol 42:5578–5581
16. Huletsky A, Lebel P, Picard FJ, Bernier M, Gagnon M, Boucher
N, Bergeron MG (2005) Identification of methicillin-resistant
Staphylococcus aureus carriage in less than 1 hour during a
hospital surveillance program. Clin Infect Dis 40:976–981
17. Bishop EJ, Grabsch EA, Ballard SA, Mayall B, Xie S, Martin R,
Grayson ML (2006) Concurrent analysis of nose and groin swab
specimens by the IDI-MRSA PCR assay is comparable to analysis
by individual-specimen PCR and routine culture assays for
detection of colonization by methicillin-resistant Staphylococcus
aureus. J Clin Microbiol 44:2904–2908
18. Van Nguyen JC, Kitzis MD, Ly A, Chalfine A, Carlet J, Ben Ali
A, Goldstein F (2006) Detection of nasal colonization methicillin-
resistant Staphylococcus aureus: a prospective study comparing
real-time genic amplification assay vs selective chromogenic
media. Pathol Biol (Paris) 54:285–292
19. Desjardins M, Guibord C, Lalonde B, Toye B, Ramotar K (2006)
Evaluation of the IDI-MRSA assay for detection of methicillin-
resistant Staphylococcus aureus from nasal and rectal specimens
pooled in a selective broth. J Clin Microbiol 44:1219–1223
20. Oliveira DC, Tomasz A, Lencastre H de (2002) Secrets of success
of a human pathogen: molecular evolution of pandemic clones of
meticillin-resistant Staphylococcus aureus. Lancet Infect Dis
2:180–189
466 Eur J Clin Microbiol Infect Dis (2007) 26:459–466
